Name: important endpoints and proliferative markers to assess small intestinal injury and adaptation using a mouse model of chemotherapy-induced mucositis
Uploaded: 2019-05-12T14:45:00
Description: Watch this Scientific Journal Video about Important Endpoints and Proliferative Markers to Assess Small Intestinal Injury and Adaptation using a Mouse Model of Chemotherapy-Induced Mucositis at JoVE.c

This work was supported by an unrestricted grant from the Novo Nordisk Center for Basic Metabolic Research and the Lundbeck Foundation.

All methods described were conducted in accordance with the guidelines of Danish legislation governing animal experimentation (1987). Studies were performed with the permission from the Danish Animal Experiments Inspectorate (2013-15-2934-00833) and the local ethical committee.
NOTE: Female C57BL/6J mice (~20&#8722;25 g) were obtained and housed eight per cage in standard 12 h light, 12 h dark cycle with free access to water and standard chow. Animals were left to acclimatize for one week befo...

<ol>
	<li>Weinstein, L. D., Shoemaker, C. P., Hersh, T., Wright, H. K. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Enhanced+intestinal+absorption+after+small+bowel+resection+in+man.">Enhanced intestinal absorption after small bowel resection in man.</a> The Archives of Surgery. 99 (5), 560-562 (1969).</li><li>Helmrath, M. A., VanderKolk, W. E., Can, G., Erwin, C. R., Warner, B. W. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Intestinal+adaptation+following+massive+small+bowel+resection+in+the+mouse.">Intestinal adaptation following massive small bowel resection in the mouse.</a> Journal of the American College of Surgeons. 183 (5), 441-449 (1996).</li><li>Kissow, H., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Exogenous+glucagon-like+peptide-2+(GLP-2)+prevents+chemotherapy-induced+mucositis+in+rat+small+intestine.">Exogenous glucagon-like peptide-2 (GLP-2) prevents chemotherapy-induced mucositis in rat small intestine.</a> Cancer Chemotherapy and Pharmacology. 70 (1), 39-48 (2012).</li><li>Kaczmarek, A., Brinkman, B. M., Heyndrickx, L., Vandenabeele, P., Krysko, D. V. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Severity+of+doxorubicin-induced+small+intestinal+mucositis+is+regulated+by+the+TLR-2+and+TLR-9+pathways.">Severity of doxorubicin-induced small intestinal mucositis is regulated by the TLR-2 and TLR-9 pathways.</a> The Journal of Pathology. 226 (4), 598-608 (2012).</li><li>Pontoppidan, P. L., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Intestinal+response+to+myeloablative+chemotherapy+in+piglets.">Intestinal response to myeloablative chemotherapy in piglets.</a> Experimental Biology and Medicine. 239 (1), 94-104 (2014).</li><li>Pontoppidan, P. L., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Associations+between+gastrointestinal+toxicity,+micro+RNA+and+cytokine+production+in+patients+undergoing+myeloablative+allogeneic+stem+cell+transplantation.">Associations between gastrointestinal toxicity, micro RNA and cytokine production in patients undergoing myeloablative allogeneic stem cell transplantation.</a> International Immunopharmacology. 25 (1), 180-188 (2015).</li><li>Crenn, P., Messing, B., Cynober, L. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Citrulline+as+a+biomarker+of+intestinal+failure+due+to+enterocyte+mass+reduction.">Citrulline as a biomarker of intestinal failure due to enterocyte mass reduction.</a> Clinical Nutrition. 27 (3), 328-339 (2008).</li><li>Fijlstra, M., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Lactose+maldigestion+during+methotrexate-induced+gastrointestinal+mucositis+in+a+rat+model.">Lactose maldigestion during methotrexate-induced gastrointestinal mucositis in a rat model.</a> American Journal of Physiology-Gastrointestinal and Liver Physiology. 300 (2), G283-G291 (2011).</li><li>Jones, J. W., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Citrulline+as+a+Biomarker+in+the+Murine+Total-Body+Irradiation+Model:+Correlation+of+Circulating+and+Tissue+Citrulline+to+Small+Intestine+Epithelial+Histopathology.">Citrulline as a Biomarker in the Murine Total-Body Irradiation Model: Correlation of Circulating and Tissue Citrulline to Small Intestine Epithelial Histopathology.</a> Health Physics. 109 (5), 452-465 (2015).</li><li>Lutgens, L. C., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Citrulline:+a+physiologic+marker+enabling+quantitation+and+monitoring+of+epithelial+radiation-induced+small+bowel+damage.">Citrulline: a physiologic marker enabling quantitation and monitoring of epithelial radiation-induced small bowel damage.</a> International Journal of Radiation Oncology, Biology, Physics. 57 (4), 1067-1074 (2003).</li><li>Demacker, P. N., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Plasma+citrulline+measurement+using+UPLC+tandem+mass-spectrometry+to+determine+small+intestinal+enterocyte+pathology.">Plasma citrulline measurement using UPLC tandem mass-spectrometry to determine small intestinal enterocyte pathology.</a> Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences. 877 (4), 387-392 (2009).</li><li>van Eijk, H. M., Rooyakkers, D. R., Deutz, N. E. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Rapid+routine+determination+of+amino+acids+in+plasma+by+high-performance+liquid+chromatography+with+a+2-3+microns+Spherisorb+ODS+II+column.">Rapid routine determination of amino acids in plasma by high-performance liquid chromatography with a 2-3 microns Spherisorb ODS II column.</a> Journal of Chromatography. 620 (1), 143-148 (1993).</li><li>Scholzen, T., Gerdes, J. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=The+Ki-67+protein:+from+the+known+and+the+unknown.">The Ki-67 protein: from the known and the unknown.</a> Journal of Cellular Physiology. 182 (3), 311-322 (2000).</li><li>Khoshyomn, S., Lew, S., DeMattia, J., Singer, E. B., Penar, P. L. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Brain+tumor+invasion+rate+measured+in+vitro+does+not+correlate+with+Ki-67+expression.">Brain tumor invasion rate measured in vitro does not correlate with Ki-67 expression.</a> Journal of Neuro-Oncology. 45 (2), 111-116 (1999).</li><li>Matatall, K. A., Kadmon, C. S., King, K. Y. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Detecting+Hematopoietic+Stem+Cell+Proliferation+Using+BrdU+Incorporation.">Detecting Hematopoietic Stem Cell Proliferation Using BrdU Incorporation.</a> Methods in Molecular Biology. , 91-103 (2018).</li><li>Hytting-Andreasen, R., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Endogenous+glucagon-like+peptide-+1+and+2+are+essential+for+regeneration+after+acute+intestinal+injury+in+mice.">Endogenous glucagon-like peptide- 1 and 2 are essential for regeneration after acute intestinal injury in mice.</a> PLoS One. 13 (6), e0198046 (2018).</li><li>Elliott, R. M., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Glucagon-like+peptide-1+(7-36)amide+and+glucose-dependent+insulinotropic+polypeptide+secretion+in+response+to+nutrient+ingestion+in+man:+acute+post-prandial+and+24-h+secretion+patterns.">Glucagon-like peptide-1 (7-36)amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: acute post-prandial and 24-h secretion patterns.</a> Journal of Endocrinology. 138 (7-36), 159-166 (1993).</li><li>Orskov, C., Wettergren, A., Holst, J. J. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Secretion+of+the+incretin+hormones+glucagon-like+peptide-1+and+gastric+inhibitory+polypeptide+correlates+with+insulin+secretion+in+normal+man+throughout+the+day.">Secretion of the incretin hormones glucagon-like peptide-1 and gastric inhibitory polypeptide correlates with insulin secretion in normal man throughout the day.</a> Scandinavian Journal of Gastroenterology. 31 (7), 665-670 (1996).</li><li>Drucker, D. J., Erlich, P., Asa, S. L., Brubaker, P. L. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Induction+of+intestinal+epithelial+proliferation+by+glucagon-like+peptide+2.">Induction of intestinal epithelial proliferation by glucagon-like peptide 2.</a> Proceedings of the National Academy of Sciences of the United States of America. 93 (15), 7911-7916 (1996).</li><li>Lee, S. J., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Disruption+of+the+murine+Glp2r+impairs+Paneth+cell+function+and+increases+susceptibility+to+small+bowel+enteritis.">Disruption of the murine Glp2r impairs Paneth cell function and increases susceptibility to small bowel enteritis.</a> Endocrinology. 153 (3), 1141-1151 (2012).</li><li>Shin, E. D., Estall, J. L., Izzo, A., Drucker, D. J., Brubaker, P. L. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Mucosal+Adaptation+to+Enteral+Nutrients+is+Dependent+on+the+Physiologic+Actions+of+Glucagon-Like+Peptide-2+in+Mice.">Mucosal Adaptation to Enteral Nutrients is Dependent on the Physiologic Actions of Glucagon-Like Peptide-2 in Mice.</a> Gastroenterology. 128 (5), 1340-1353 (2005).</li><li>Tsai, C. H., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Intestinal+growth-promoting+properties+of+glucagon-like+peptide-2+in+mice.">Intestinal growth-promoting properties of glucagon-like peptide-2 in mice.</a> American Journal of Physiology-Endocrinology and Metabolism. 273 (1), E77-E84 (1997).</li><li>Sangild, P. T., Shen, R. L., Pontoppidan, P., Rathe, M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Animal+models+of+chemotherapy-induced+mucositis:+translational+relevance+and+challenges.">Animal models of chemotherapy-induced mucositis: translational relevance and challenges.</a> American Journal of Physiology-Gastrointestinal and Liver Physiology. 314 (2), G231-G246 (2017).</li><li>Gibson, R. J., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Irinotecan+causes+severe+small+intestinal+damage,+as+well+as+colonic+damage,+in+the+rat+with+implanted+breast+cancer.">Irinotecan causes severe small intestinal damage, as well as colonic damage, in the rat with implanted breast cancer.</a> Journal of Gastroenterology and Hepatology. 18 (9), 1095-1100 (2003).</li><li>Zhang, C., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Bone+marrow+stromal+cells+upregulate+expression+of+bone+morphogenetic+proteins+2+and+4,+gap+junction+protein+connexin-43+and+synaptophysin+after+stroke+in+rats.">Bone marrow stromal cells upregulate expression of bone morphogenetic proteins 2 and 4, gap junction protein connexin-43 and synaptophysin after stroke in rats.</a> Neuroscience. 141 (2), 687-695 (2006).</li><li>Biebl, M., Cooper, C. M., Winkler, J., Nl Kuhn, H. G. J. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Analysis+of+neurogenesis+and+programmed+cell+death+reveals+a+self-renewing+capacity+in+the+adult+rat+brain.">Analysis of neurogenesis and programmed cell death reveals a self-renewing capacity in the adult rat brain.</a> Neuroscience Letters. 291 (1), 17-20 (2000).</li></ol>

Here, we demonstrate a widely accessible method to study SI injury and regeneration in a mouse model. A wide variety of preclinical animal models of intestinal injury exist, but it is vital we understand that each model is unique and that the endpoints must be appropriate to answer the research question. This model is excellent to study adaptive response to injury, but the endpoints should be modified when using the model as a pre-clinical model of mucositis. However, translation from animal models to patients is challen...

Intestinal adaptation is the natural compensatory mechanism that occurs when the bowel is lost due to disease or surgery1,2. After trauma, the gut undergoes a morphometric and functional adaptive response, characterized by crypt cell proliferation and increased nutrient absorption3. This step is critical in recovery, yet poorly understood. Experimental studies of the intestinal adaptive response have focused on the changes occurring after small bowel resection in mice, rats, and pigs, but understanding the molecular mechanism behind the adaptive response in other kinds of injuries (e.g., chemical or bacterial) is crucial to facilitate the identification of nutrients or drugs to enhance adaptation. Experimentally, different approaches have been used to describe the complex molecular and cellular index of small intestinal pathology, including histopathological scoring and measuring the outcome of injury. Despite this, what is absent from the literature is a detailed description of how to perform the procedures that are needed to obtain reproducible data. When identifying factors involved in adaptation, such as gut hormones, an easy, low cost, and reproducible animal model is warranted and here we suggest using a model of chemotherapy-induced intestinal mucositis (CIM).
One of the simplest and very informative endpoints of both injury and adaptation is to measure the mass of the small intestine (SI). We know that a hallmark of mucositis is apoptosis of enterocytes, time-dependent villus atrophy and reduced mitosis. Therefore, examining intestinal morphology is highly relevant in preclinical models4,5. In humans, a decline in plasma citrulline, a marker of functioning enterocytes, correlates with toxicity scores and inflammatory markers6 in addition to the absorptive capacity7, suggesting this amino acid is an excellent biomarker of mucositis. Citrulline can be measured in both mice and rats, and has shown excellent correlations with villus length8, crypt survival9, and radiation-induced mucositis10.
A major advantage of measuring plasma citrulline is the ability to collect repeated measurements from one animal. However, multiple blood sampling in mice is restricted to a total blood volume of 6 &#181;L/g/week and requires general anaesthesia. This unfortunately also limits the use of citrulline measurements in mice. Furthermore, the measurement of citrulline requires high-performance liquid chromatography11,12, which is costly and time-consuming. Recently, we showed that citrulline levels in mice correlate significantly with SI weight (p &#60; 0.001) (unpublished data), making citrulline a direct measurement reflecting enterocyte mass. A limitation to the measurement of SI weight is the necessity for the mice to be sacrificed and thus no repeated measurements within the same mouse are possible. Still the method provides the possibility to perform a variety of other tissue analyses directed to the research question, and these facts can conceivably make up for the additional use of animals. We, therefore, suggest using SI weight as an easy, low-cost, and fast biomarker of injury and adaptation in mice. To ensure reproducibility and acceptable analytic variation, the intestines should be carefully removed from the animal, flushed with saline, emptied and dried before weighing. In this article, we show exactly how this procedure is performed.
Another hallmark of mucositis is the loss of the proliferating cells in the crypts and a compensatory hyperproliferation during the regenerative period3. The cellular marker Ki67 has been frequently used to determine fast proliferative cells by means of immunohistochemistry13. Even though Ki67 is a simple marker of proliferation, it has a tendency for imprecision as Ki67 is present during all active phases of the cell cycle (G1, S, G2, and M)14. Specific labelling is essential to detect replicating cells, which is why we suggest in situ incorporation of 5-bromo-2&#39;-deoxyuridine (BrdU), a synthetic analogue of thymidine, as it is largely restricted to replicating cells in the S-phase15. BrdU is injected in the animals 150 minutes before sacrificing and cells can be subsequently detected with immunohistochemistry using BrdU specific antibodies. In this method article, we show exactly how to measure the area of BrdU immunopositive cells within a crypt using a free image software.
Morphologic and functional changes are often studied in 5-FU induced mucositis models, where the intestinal adaptation is assessed by villus height and crypt depth. During this study, we found that during the acute phase of mucositis, which is equal to the injury phase, proliferation measured by BrdU incorporation is not correlated with crypt depth. In contrast to this, crypt depth is significantly correlated with proliferation seen in the repair phase of mucositis, 3 to 5 days after induction. This suggests that the acute phase of mucositis is not measurable by crypt depth alone. We suggest that when using proliferation as an endpoint in the acute phase of mucositis mice, BrdU incorporation should preferably be used but when quantitating hyperproliferation in the later stage during the regenerative phase, crypt depth is a reasonable alternative to BrdU incorporation. The goal of this study was to describe this model in a way that it can be used by all researchers, both in the field of oncology but especially researchers not familiar with intestinal injury models.
The described model can be used to phenotype transgenic models according to the adaptive response using body weight, SI weight and crypt depth as endpoints. As an example, we show here how we used the model of 5-fluorouracil (5-FU) induced mucositis in a cellular knock out model with insufficient L-cell secretion16. Glucagon-like peptide-1 (GLP-1) and glucagon-like peptide-2 (GLP-2) are intestinal hormones co-secreted from the enteroendocrine L-cells in response to food intake17,18. GLP-2 is recognized as an important factor for intestinal healing, the regulation of mucosal apoptosis and the improvement of the barrier function of the SI19,20,21,22. Based on the literature, we hypothesized that endogenous hormones are essential for compensatory hyperproliferation occurring in the adaptive response after injury.

<table>
	<tbody>
		<tr>
			<td>5-Fluorouracil</td>
			<td>Hospira Nordic AB, Sweden</td>
			<td>137853</td>
			<td></td>
		</tr>
		<tr>
			<td>Ketaminol&#174;Vet</td>
			<td>Merck, New Jersey, USA</td>
			<td>511485</td>
			<td></td>
		</tr>
		<tr>
			<td>Rompun&#174;Vet Xylazine</td>
			<td>Rompunvet, Bayer, Leverkusen, Germany.</td>
			<td>148999</td>
			<td></td>
		</tr>
		<tr>
			<td>10% nautral formalin buffer</td>
			<td>Cell Path Ltd, Powys, United Kingdom</td>
			<td>BAF-5000-08A</td>
			<td></td>
		</tr>
		<tr>
			<td>HistoClear</td>
			<td>National Diagnostics, United Kingdom</td>
			<td>HS-200</td>
			<td></td>
		</tr>
		<tr>
			<td>Pertex</td>
			<td>HistoLab&#174;, Sweden</td>
			<td>840</td>
			<td></td>
		</tr>
		<tr>
			<td>BrdU</td>
			<td>Sigma-Aldrich, Germany.</td>
			<td>B5002</td>
			<td></td>
		</tr>
		<tr>
			<td>Tris/EDTA pH 9 buffer</td>
			<td>Thermofisher scientific, Denmark</td>
			<td>TA-125-PM4X</td>
			<td></td>
		</tr>
		<tr>
			<td>Peroxide Block</td>
			<td>Ultravision Quanto Mouse on Mouse kit, Thermofisher Scientific, Denmark</td>
			<td>TL-060-QHDM</td>
			<td></td>
		</tr>
		<tr>
			<td>Rodent Block buffer</td>
			<td>Ultravision Quanto Mouse on Mouse kit, Thermofisher Scientific, Denmark</td>
			<td>TL-060-QHDM</td>
			<td></td>
		</tr>
		<tr>
			<td>Monoclonal mouse anti-BrdU antibody</td>
			<td>Thermofisher Scientific, Denmark.</td>
			<td>MA1-81890</td>
			<td></td>
		</tr>
		<tr>
			<td>Lab Vision Antibody Diluent OP Quanto</td>
			<td>Thermofisher Scientific, Denmark.</td>
			<td>TA-125-ADQ</td>
			<td></td>
		</tr>
		<tr>
			<td>Horseradish peroxidase</td>
			<td>Ultravision Quanto Mouse on Mouse kit, Thermofisher Scientific, Denmark</td>
			<td>TL-060-QHDM</td>
			<td></td>
		</tr>
		<tr>
			<td>DAB Quanto Substrate</td>
			<td>DAB Substrate Kit, Thermofisher Scientific, Denmark</td>
			<td>TA-125-QHDX</td>
			<td></td>
		</tr>
		<tr>
			<td>DAB Quanto Chromogen</td>
			<td>DAB Substrate Kit, Thermofisher Scientific, Denmark</td>
			<td>TA-125-QHDX</td>
			<td></td>
		</tr>
		<tr>
			<td>Zen Lite Software (Blue edition)</td>
			<td>Carl Zeiss A/S</td>
			<td></td>
			<td>https://www.zeiss.com/microscopy/int/products/microscope-software/zen-lite.html</td>
		</tr>
		<tr>
			<td>ImageJ Software</td>
			<td>LOCI, University of Wisconsin</td>
			<td></td>
			<td>https://imagej.nih.gov/ij/</td>
		</tr>
	</tbody>
</table>

important endpoints and proliferative markers to assess small intestinal injury and adaptation using a mouse model of chemotherapy-induced mucositis

Intestinal adaptation is the natural compensatory mechanism that occurs when the bowel is lost due to trauma. The adaptive responses, such as crypt cell proliferation and increased nutrient absorption, are critical in recovery, yet poorly understood. Understanding the molecular mechanism behind the adaptive responses is crucial to facilitate the identification of nutrients or drugs to enhance adaptation. Different approaches and models have been described throughout the literature, but a detailed descriptive way to essentially perform the procedures is needed to obtain reproducible data. Here, we describe a method to estimate important endpoints and proliferative markers of small intestinal injury and compensatory hyperproliferation using a model of chemotherapy-induced mucositis in mice. We demonstrate the detection of proliferating cells using a cell cycle specific marker, as well as using small intestinal weight, crypt depth, and villus height as endpoints. Some of the critical steps within the described method are the removal and weighing of the small intestine and the rather complex software system suggested for the measurement of this technique. These methods have the advantages that they are not time-consuming, and that they are cost-effective and easy to carry out and measure.

In the first experiment, we induced mucositis in mice at day 0 and sacrificed a group of mice each day for 5 consecutive days. When measuring the SI weight, we found that this parameter decreased from day 2 until day 4 suggesting a loss in the enterocyte mass. We also found that at day 5, the SI weight was not significantly different from day 0 (untreated mice) (Figure 1). The proliferation measured by the incorporation of BrdU was almost abolished at day 1 a...

Watch this Scientific Journal Video about Important Endpoints and Proliferative Markers to Assess Small Intestinal Injury and Adaptation using a Mouse Model of Chemotherapy-Induced Mucositis at JoVE.c

Important Endpoints and Proliferative Markers to Assess Small Intestinal Injury and Adaptation using a Mouse Model of Chemotherapy-Induced Mucositis

Here, we present a protocol to establish important endpoints and proliferative markers of small intestinal injury and compensatory hyperproliferation using a model of chemotherapy-induced mucositis. We demonstrate the detection of proliferating cells using a cell cycle specific marker and using small intestinal weight, crypt depth, and villus height as endpoints.

Intestinal adaptation is the natural compensatory mechanism that occurs when the bowel is lost due to trauma. The adaptive responses, such as crypt cell ...

This model of chemotherapy-induced mucositis can be used to determine important endpoints and proliferated markers of small intestinal injury and compensatory hyperproliferation in mice. This method is time and cost efficient and easy to carry out. With a standardized method like this, it is easier to compare analytic endpoints with few variations.For 5-Florauracil or 5FU mucositis induction, load a 1-milliliter syringe equipped with a 27 gauge by 19 millimeter needle with the appropriate volume of 5FU and manually restrain a recipient mouse. While maintaining the mouse in a firm but gentle grip, expose the ventral side of the animal and insert the needle into the intraparitoneal cavity within one of the lower quadrants of the abdomen. Then, aspirate to ensure proper needle placement and inject the 5FU.At the appropriate experimental endpoint, 4-Bromo-Deoxyuridine or BrdU quantification, weigh a 5FU injured animal mouse and deliver 5 milligrams per kilogram of BrdU by intraperitoneal injection in a fume hood. 150 minutes after the BrdU injetion, confirm a lack of response to toe pinch, record the weight of the anesthetized mouse, and place the animal in the supine position. Perform a laparotomy to expose the abdominal cavity and make an incision of the chest cavity to introduce pneumothorax.Cut superior to the pylorus, and carefully extract retract the intestinal tissue away from the animal until the cecum is reached. Using forceps, gently clamp the proximal lumen shut and use a 10 milliliter syringe equipped with a 25 gauge needle to flush the small intestine with saline. Then place the emptied intestine onto clean blotting paper to carefully remove the excess salt solution.For tissue collection, harvest the small intestine from the injected animal as just demonstrated and record the weight of the flushed tissue. After histological processing, the tissue can be imaged under the 10x objective of a light microscope connected to a camera to obtain histological photos of the harvested tissue. To measure the area of the BrdU immunoreactive cells, open the image of interest in image J, and open the stage micrometer image.Use the straight line selection tool to draw a straight line on micrometer image to define a known distance and select set scale in the analyze menu. Enter a value in the known distance box, and define the unit of length in the unit of length box. Open an image of interest to measure the area of the BrdU immunoreactive cells per crypt, and set the color graphics to 8-bit under the image type menu.Increase the contrast of the image under process-enhanced contrast, and set the saturated pixels to 0.4%Apply a threshold to the image to segment the immuno-positivity and select image adjust. Select threshold and red, moving the threshold bar to select a threshold of around 10 to 20 percent. Then select a well-oriented crypt, and use the freehand selection tool to mark the area around it.To measure the threshold area, open the analyze tab and select analyze particles. In the analyze particle window, set the size to 20 to infinity, and click the box pixel units. Set the circularity to zero to one, and set show to outlines.Then click the display results, summarize, and include holes boxes. The measurement results will be displayed in the summary window. To measure the crypt depth, open an image in Zen Light and connect to the camera.Take snapshots in camera mode with a 20x objective, and switch to processing mode to open the snapshot. Switch to the measure view. Use the line tool to start a line at the bottom of a well-oriented crypt, finishing the line at the top of the crypt.Then export the measurements and calculate the average of the crypt depth and fill as height. The small intestine weight decreases from day 2 until day 4, suggesting a loss in the enterocyte mass. Of note, by day 5, the weight is not significantly different than the weight of day 0 on treated animals.The measured proliferation by BrdU incorporation is almost abolished at days 1 and 2, but at days 4 and 5, there are approximately four-and five-fold increases in their proliferation, respectively. This hyperproliferation is also observed when measuring the crypt depth. In the regenerative phase of mucositis, there is a strong correlation between BrdU incorporation and crypt depth that is not observed during the acute phase, suggesting that using crypt depth as an endpoint might be suitable in the acute phase of mucositis.Transgenic mice, with an insufficient L-cell secretion, demonstrate a significant loss of body weight and a decrease in small intestine weight in the recovery phase, compared to that observed in wild type 5-FU mice. Further, the transgenic mice fail to show compensatory hyperproliferation as the crypts are significantly shorter than in both wild-type mice and healthy controls. While attempting this procedure, make sure to empty the small intestine completely, and to remove the excess saline before weighing the tissue to obtain the small intestinal weight weight only.After watching this video, you should have a good understanding of how to conduct, collect, and determine important endpoints of small intestinal injury. And to effectively obtain reproducible data. Don't forget that working with chemical compounds such as 5FU and BrdU can be hazardous and that precautions, such as using a lab coat, gloves, and a fume hood should always be taken when performing these procedures.

important-endpoints-proliferative-markers-to-assess-small-intestinal

Research

JoVE Journal

Cancer Research

A Mouse Model of Fatigue Induced by Peripheral Irradiation

Cancer-related fatigue (CRF) is a distressing and costly condition that often affects patients receiving cancer treatments, including radiation therapy. Here we describe a method using targeted peripheral irradiation to induce fatigue-like behavior in mice. With appropriate shielding, the irradiation targets the lower abdominal/pelvic region of the mouse, sparing the brain, in an effort to model radiation treatment received by individuals with pelvic cancers. We deliver an irradiation dose that is sufficient to induce fatigue-like behavior in mice, measured by voluntary wheel-running activity (VWRA), without causing obvious morbidity. Since wheel running is a normal, voluntary behavior in mice, its use should have little confounding effect on other behavioral tests or biological measures. Hence, wheel running can be used as a feasible outcome measure in understanding the behavioral and biological correlates of fatigue. CRF is a complex condition with frequent comorbidities, and likely has causes related both to cancer and its various treatments. The methods described in this paper are useful for investigating radiation-induced changes that contribute to the development of CRF and, more generally, to explore the biological networks that can explain the development and persistence of a peripherally-triggered but centrally-driven behavior like fatigue.

We describe a method using targeted peripheral irradiation to induce fatigue-like behavior in mice. The selected non-lethal irradiation dose leads to a week-long reduction in voluntary wheel-running activity.

Cancer-related fatigue (CRF) is a distressing and costly condition that often affects patients receiving cancer treatments, including radiation therapy. ...

A Genetically Engineered Mouse Model of Sporadic Colorectal Cancer

Despite the advantages of easy applicability and cost-effectiveness, colorectal cancer mouse models based on tumor cell injection have severe limitations and do not accurately simulate tumor biology and tumor cell dissemination. Genetically engineered mouse models have been introduced to overcome these limitations; however, such models are technically demanding, especially in large organs such as the colon in which only a single tumor is desired.
As a result, an immunocompetent, genetically engineered mouse model of colorectal cancer was developed which develops highly uniform tumors and can be used for tumor biology studies as well as therapeutic trials. Tumor development is initiated by surgical, segmental infection of the distal colon with adeno-cre virus in compound conditionally mutant mice. The tumors can be easily detected and monitored via colonoscopy. We here describe the surgical technique of segmental adeno-cre infection of the colon, the surveillance of the tumor via high-resolution colonoscopy and present the resulting colorectal tumors.

A protocol for the establishment of a genetically engineered mouse model of colorectal cancer by segmental adeno-cre infection and its surveillance via high-resolution colonoscopy is presented.

Despite the advantages of easy applicability and cost-effectiveness, colorectal cancer mouse models based on tumor cell injection have severe limitations ...

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

B lymphocytes are key players in immune cell circulation and they mainly home to and reside in lymphoid organs. While normal B cells only proliferate when stimulated by T lymphocytes, oncogenic B cells survive and expand autonomously in undefined organ niches. Mantle cell lymphoma (MCL) is one such B cell disorder, where the median survival rate of patients is 4 - 5 years. This calls for the need of effective mechanisms by which the homing and engraftment of these cells are blocked in order to increase the survival and longevity of patients. Therefore, the effort to develop a xenograft mouse model to study the efficacy of MCL therapeutics by blocking the homing mechanism in vivo is of utmost importance. Development of animal recipients for human cell xenotransplantation to test early stage drugs have long been pursued, as relevant preclinical mouse models are crucial to screen new therapeutic agents. This animal model is developed to avoid human graft rejection and to establish a model for human diseases, and it may be an extremely useful tool to study disease progression of different lymphoma types and to perform preclinical testing of candidate drugs for hematologic malignancies, like MCL. We established a xenograft mouse model that will serve as an excellent resource to study and develop novel therapeutic approaches for MCL.

Mantle cell lymphoma (MCL) is a difficult to treat B cell disorder and it is equally difficult to establish a xenograft mouse model of primary MCL to study and develop therapeutics. Here, we describe the successful establishment of MCL xenografts in mice to help understand its underlying biology.

B lymphocytes are key players in immune cell circulation and they mainly home to and reside in lymphoid organs. While normal B cells only proliferate when ...

PET and MRI Guided Irradiation of a Glioblastoma Rat Model Using a Micro-irradiator

For decades, small animal radiation research was mostly performed using fairly crude experimental setups applying simple single-beam techniques without the ability to target a specific or well-delineated tumor volume. The delivery of radiation was achieved using fixed radiation sources or linear accelerators producing megavoltage (MV) X-rays. These devices are unable to achieve sub-millimeter precision required for small animals. Furthermore, the high doses delivered to healthy surrounding tissue hamper response assessment. To increase the translation between small animal studies and humans, our goal was to mimic the treatment of human glioblastoma in a rat model. To enable a more accurate irradiation in a preclinical setting, recently, precision image-guided small animal radiation research platforms were developed. Similar to human planning systems, treatment planning on these micro-irradiators is based on computed tomography (CT). However, low soft-tissue contrast on CT makes it very challenging to localize targets in certain tissues, such as the brain. Therefore, incorporating magnetic resonance imaging (MRI), which has excellent soft-tissue contrast compared to CT, would enable a more precise delineation of the target for irradiation. In the last decade also biological imaging techniques, such as positron emission tomography (PET) gained interest for radiation therapy treatment guidance. PET enables the visualization of e.g., glucose consumption, amino-acid transport, or hypoxia, present in the tumor. Targeting those highly proliferative or radio-resistant parts of the tumor with a higher dose could give a survival benefit. This hypothesis led to the introduction of the biological tumor volume (BTV), besides the conventional gross target volume (GTV), clinical target volume (CTV), and planned target volume (PTV).
At the preclinical imaging lab of Ghent University, a micro-irradiator, a small animal PET, and a 7 T small animal MRI are available. The goal was to incorporate MRI-guided irradiation and PET-guided sub-volume boosting in a glioblastoma rat model.

In the past, small animal irradiation was usually performed without the ability to target a well-delineated tumor volume. The goal was to mimic the treatment of human glioblastoma in rats. Using a small animal irradiation platform, we performed MRI-guided 3D conformal irradiation with PET-based sub-volume boosting in a preclinical setting.

For decades, small animal radiation research was mostly performed using fairly crude experimental setups applying simple single-beam techniques without ...

A Preclinical Mouse Model of Osteosarcoma to Define the Extracellular Vesicle-mediated Communication Between Tumor and Mesenchymal Stem Cells

Within the tumor microenvironment, resident or recruited mesenchymal stem cells (MSCs) contribute to malignant progression in multiple cancer types. Under the influence of specific environmental signals, these adult stem cells can release paracrine mediators leading to accelerated tumor growth and metastasis. Defining the crosstalk between tumor and MSCs is of primary importance to understand the mechanisms underlying cancer progression and identify novel targets for therapeutic intervention. 
Cancer cells produce high amounts of extracellular vesicles (EVs), which can profoundly affect the behavior of target cells in the tumor microenvironment or at distant sites. Tumor EVs enclose functional biomolecules, including inflammatory RNAs and (onco)proteins, that can educate stromal cells to enhance the metastatic behavior of cancer cells or to participate in the pre-metastatic niche formation. In this article, we describe the development of a preclinical cancer mouse model that enables specific evaluation of the EV-mediated crosstalk between tumor and mesenchymal stem cells. First, we describe the purification and characterization of tumor-secreted EVs and the assessment of the EV internalization by MSCs. We then make use of a multiplex bead-based immunoassay to evaluate the alteration of the MSC cytokine expression profile induced by cancer EVs. Finally, we illustrate the generation of a bioluminescent orthotopic xenograft mouse model of osteosarcoma that recapitulates the tumor-MSC interaction, and show the contribution of EV-educated MSCs to tumor growth and metastasis formation. 
Our model provides the opportunity to define how cancer EVs shape a tumor-supporting environment, and to evaluate whether blockade of the EV-mediated communication between tumor and MSCs prevents cancer progression.

Direct injection of cancer-derived extracellular vesicles (EVs) leads to reprogramming of bone marrow supporting tumor progression; however, which cells mediate this effect is unclear. Herein, we describe a step-by-step protocol to investigate EV-mediated tumor-mesenchymal stem cell (MSC) interactions in vivo, revealing a crucial role for EV-educated MSCs in metastasis.

Within the tumor microenvironment, resident or recruited mesenchymal stem cells (MSCs) contribute to malignant progression in multiple cancer types. Under ...

Long-term Live-cell Imaging to Assess Cell Fate in Response to Paclitaxel

Live-cell imaging is a powerful technique that can be used to directly visualize biological phenomena in single cells over extended periods of time. Over the past decade, new and innovative technologies have greatly enhanced the practicality of live-cell imaging. Cells can now be kept in focus and continuously imaged over several days while maintained under 37 &#176;C and 5% CO2 cell culture conditions. Moreover, multiple fields of view representing different experimental conditions can be acquired simultaneously, thus providing high-throughput experimental data. Live-cell imaging provides a significant advantage over fixed-cell imaging by allowing for the direct visualization and temporal quantitation of dynamic cellular events. Live-cell imaging can also identify variation in the behavior of single cells that would otherwise have been missed using population-based assays. Here, we describe live-cell imaging protocols to assess cell fate decisions following treatment with the anti-mitotic drug paclitaxel. We demonstrate methods to visualize whether mitotically arrested cells die directly from mitosis or slip back into interphase. We also describe how the fluorescent ubiquitination-based cell cycle indicator (FUCCI) system can be used to assess the fraction of interphase cells born from mitotic slippage that are capable of re-entering the cell cycle. Finally, we describe a live-cell imaging method to identify nuclear envelope rupture events.

Live-cell imaging provides a wealth of information on single cells or whole populations that is unattainable by fixed cell imaging alone. Here, live-cell imaging protocols to assess cell fate decisions following treatment with the anti-mitotic drug paclitaxel are described.

Live-cell imaging is a powerful technique that can be used to directly visualize biological phenomena in single cells over extended periods of time. Over ...

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype with limited therapeutic options. When compared to patients with less aggressive breast tumors, the 5-year survival rate of TNBC patients is 77% due to their characteristic drug-resistant phenotype and metastatic burden. Toward this end, murine models have been established aimed at identifying novel therapeutic strategies limiting TNBC tumor growth and metastatic spread. This work describes a practical guide for the TNBC orthotopic model where MDA-MB-231 breast cancer cells suspended in a basement membrane matrix are implanted in the fourth mammary fat pad, which closely mimics the cancer cell behavior in humans. Measurement of tumors by caliper, lung metastasis assessment via in vivo and ex vivo imaging, and molecular detection are discussed. This model provides an excellent platform to study therapeutic efficacy and is especially suitable for the study of the interaction between the primary tumor and distal metastatic sites.

This work presets an advanced protocol to accurately assess tumor loading by detection of green fluorescent protein and bioluminescence signals as well as the integration of quantitative molecular detection technique.

Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype with limited therapeutic options. When compared to patients with less ...

Using Computer-based Image Analysis to Improve Quantification of Lung Metastasis in the 4T1 Breast Cancer Model

Breast cancer is a devastating malignancy, accounting for 40,000 female deaths and 30% of new female cancer diagnoses in the United States in 2019 alone. The leading cause of breast cancer related deaths is the metastatic burden. Therefore, preclinical models for breast cancer need to analyze metastatic burden to be clinically relevant. The 4T1 breast cancer model provides a spontaneously-metastasizing, quantifiable mouse model for stage IV human breast cancer. However, most 4T1 protocols quantify the metastatic burden by manually counting stained colonies on tissue culture plates. While this is sufficient for tissues with lower metastatic burden, human error in manual counting causes inconsistent and variable results when plates are confluent and difficult to count. This method offers a computer-based solution to human counting error. Here, we evaluate the protocol using the lung, a highly metastatic tissue in the 4T1 model. Images of methylene blue-stained plates are acquired and uploaded for analysis in Fiji-ImageJ. Fiji-ImageJ then determines the percentage of the selected area of the image that is blue, representing the percentage of the plate with metastatic burden. This computer-based approach offers more consistent and expeditious results than manual counting or histopathological evaluation for highly metastatic tissues. The consistency of Fiji-ImageJ results depends on the quality of the image. Slight variations in results between images can occur, thus it is recommended that multiple images are taken and results averaged. Despite its minimal limitations, this method is an improvement to quantifying metastatic burden in the lung by offering consistent and rapid results.

We describe a more consistent and expeditious method to quantify lung metastasis in the 4T1 breast cancer model by using Fiji-ImageJ.

Breast cancer is a devastating malignancy, accounting for 40,000 female deaths and 30% of new female cancer diagnoses in the United States in 2019 alone. ...

A Mouse Model to Investigate the Role of Cancer-Associated Fibroblasts in Tumor Growth

Cancer-associated fibroblasts (CAFs) can play an important role in tumor growth by creating a tumor-promoting microenvironment. Models to study the role of CAFs in the tumor microenvironment can be helpful for understanding the functional importance of fibroblasts, fibroblasts from different tissues, and specific genetic factors in fibroblasts. Mouse models are essential for understanding the contributors to tumor growth and progression in an in vivo context. Here, a protocol in which cancer cells are mixed with fibroblasts and introduced into mice to develop tumors is provided. Tumor sizes over time and final tumor weights are determined and compared among groups. The protocol described can provide more insight into the functional role of CAFs in tumor growth and progression.

A protocol to co-inject cancer cells and fibroblasts and monitor tumor growth over time is provided. This protocol can be used to understand the molecular basis for the role of fibroblasts as regulators of tumor growth.

Cancer-associated fibroblasts (CAFs) can play an important role in tumor growth by creating a tumor-promoting microenvironment. Models to study the role ...

Positron Emission Tomography-based Dose Painting Radiation Therapy in a Glioblastoma Rat Model using the Small Animal Radiation Research Platform

A rat glioblastoma model to mimic chemo-radiation treatment of human glioblastoma in the clinic was previously established. Similar to the clinical treatment, computed tomography (CT) and magnetic resonance imaging (MRI) were combined during the treatment-planning process. Positron emission tomography (PET) imaging was subsequently added to implement sub-volume boosting using a micro-irradiation system. However, combining three imaging modalities (CT, MRI, and PET) using a micro-irradiation system proved to be labor-intensive because multimodal imaging, treatment planning, and dose delivery have to be completed sequentially in the preclinical setting. This also results in a workflow that is more prone to human error. Therefore, a user-friendly algorithm to further optimize preclinical multimodal imaging-based radiation treatment planning was implemented. This software tool was used to evaluate the accuracy and efficiency of dose painting radiation therapy with micro-irradiation by using an in silico study design. The new methodology for dose painting radiation therapy is superior to the previously described method in terms of accuracy, time efficiency, and intra- and inter-user variability. It is also an important step towards the implementation of inverse treatment planning on micro-irradiators, where forward planning is still commonly used, in contrast to clinical systems.

Here we present a protocol to perform preclinical positron emission tomography-based radiotherapy in a rat glioblastoma model using algorithms developed in-house to optimize the accuracy and efficiency.

A rat glioblastoma model to mimic chemo-radiation treatment of human glioblastoma in the clinic was previously established. Similar to the clinical ...